Nanomedicine-mediated regulated cell death in cancer immunotherapy.
Nanomedicine-mediated regulated cell death in cancer immunotherapy.
复制标题
DOI:
10.1016/j.jconrel.2023.10.032
复制
发表时间:
2023-10
期刊:
影响因子:
--
通讯作者:
Yue Sun;Ting Lian;Qichao Huang;Yawei Chang;Yuan Li;Xiaoyu Guo;Weirong Kong;Yifang Yang
中科院分区:
文献类型:
--
作者:
Yue Sun;Ting Lian;Qichao Huang;Yawei Chang;Yuan Li;Xiaoyu Guo;Weirong Kong;Yifang Yang
Immunotherapy has attracted widespread attention in cancer treatment and has achieved considerable success in the clinical treatment of some tumors, but it has a low response rate in most tumors. To achieve sufficient activation of the immune response, significant efforts using nanotechnology have been made to enhance cancer immune response. In recent years, the induction of various regulated cell death (RCD) has emerged as a potential antitumor immuno-strategy, including processes related to apoptosis, autophagy, necroptosis, pyroptosis, ferroptosis, and cuproptosis. In particular, damage-associated molecular patterns (DAMPs) released from the damaged membrane of dying cells act asin situadjuvants to trigger antigen-specific immune responses by the exposure of an increased antigenicity. Thus, RCD-based immunotherapy offers a new approach for enhancing cancer treatment efficacy. Furthermore, incorporation with multimodal auxiliary therapies in cell death-based immunotherapy can trigger stronger immune responses, resulting in more efficient therapeutic outcome. This review discusses different RCD modalities and summarizes recent nanotechnology-mediated RCDs in cancer immunotherapy.